Treatment with glucagon‐like peptide‐1 receptor agonists and incidence of dementia: Data from pooled double‐blind randomized controlled trials and nationwide disease and prescription registers
Abstract Introduction People with type 2 diabetes have increased risk of dementia. Glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs) are among the promising therapies for repurposing as a treatment for Alzheimer's disease; a key unanswered question is whether they reduce dementia incidenc...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Alzheimer’s & Dementia: Translational Research & Clinical Interventions |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/trc2.12268 |
| _version_ | 1797949002049650688 |
|---|---|
| author | Caroline Holm Nørgaard Sarah Friedrich Charlotte Thim Hansen Thomas Gerds Clive Ballard Daniel Vega Møller Lotte Bjerre Knudsen Kajsa Kvist Bernard Zinman Ellen Holm Christian Torp‐Pedersen Lina Steinrud Mørch |
| author_facet | Caroline Holm Nørgaard Sarah Friedrich Charlotte Thim Hansen Thomas Gerds Clive Ballard Daniel Vega Møller Lotte Bjerre Knudsen Kajsa Kvist Bernard Zinman Ellen Holm Christian Torp‐Pedersen Lina Steinrud Mørch |
| author_sort | Caroline Holm Nørgaard |
| collection | DOAJ |
| description | Abstract Introduction People with type 2 diabetes have increased risk of dementia. Glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs) are among the promising therapies for repurposing as a treatment for Alzheimer's disease; a key unanswered question is whether they reduce dementia incidence in people with type 2 diabetes. Methods We assessed exposure to GLP‐1 RAs in patients with type 2 diabetes and subsequent diagnosis of dementia in two large data sources with long‐term follow‐up: pooled data from three randomized double‐blind placebo‐controlled cardiovascular outcome trials (15,820 patients) and a nationwide Danish registry‐based cohort (120,054 patients). Results Dementia rate was lower both in patients randomized to GLP‐1 RAs versus placebo (hazard ratio [HR]: 0.47 (95% confidence interval [CI]: 0.25–0.86) and in the nationwide cohort (HR: 0.89; 95% CI: 0.86–0.93 with yearly increased exposure to GLP‐1 RAs). Discussion Treatment with GLP‐1 RAs may provide a new opportunity to reduce the incidence of dementia in patients with type 2 diabetes. |
| first_indexed | 2024-04-10T21:53:35Z |
| format | Article |
| id | doaj.art-a3a27f9ddbfd4e1cafdac0c2aea95168 |
| institution | Directory Open Access Journal |
| issn | 2352-8737 |
| language | English |
| last_indexed | 2024-04-10T21:53:35Z |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Alzheimer’s & Dementia: Translational Research & Clinical Interventions |
| spelling | doaj.art-a3a27f9ddbfd4e1cafdac0c2aea951682023-01-18T11:41:03ZengWileyAlzheimer’s & Dementia: Translational Research & Clinical Interventions2352-87372022-01-0181n/an/a10.1002/trc2.12268Treatment with glucagon‐like peptide‐1 receptor agonists and incidence of dementia: Data from pooled double‐blind randomized controlled trials and nationwide disease and prescription registersCaroline Holm Nørgaard0Sarah Friedrich1Charlotte Thim Hansen2Thomas Gerds3Clive Ballard4Daniel Vega Møller5Lotte Bjerre Knudsen6Kajsa Kvist7Bernard Zinman8Ellen Holm9Christian Torp‐Pedersen10Lina Steinrud Mørch11Department of Cardiology and Clinical Research Nordsjællands University Hospital Hillerød DenmarkDepartment of Medical Statistics University Medical Center Göttingen Göttingen GermanyNovo Nordisk Søborg DenmarkSection of Biostatistics Copenhagen University Østerbro DenmarkSt Luke's Campus University of Exeter College of Medicine and Health Exeter UKNovo Nordisk Søborg DenmarkNovo Nordisk Måløv DenmarkNovo Nordisk Søborg DenmarkLunenfeld–Tanenbaum Research Institute Mount Sinai Hospital University of Toronto Toronto Ontario CanadaDepartment of Medicine Nykøbing Falster Hospital Hospitalsvej Nykøbing Falster DenmarkDepartment of Cardiology and Clinical Research Nordsjællands University Hospital Hillerød DenmarkNovo Nordisk Søborg DenmarkAbstract Introduction People with type 2 diabetes have increased risk of dementia. Glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs) are among the promising therapies for repurposing as a treatment for Alzheimer's disease; a key unanswered question is whether they reduce dementia incidence in people with type 2 diabetes. Methods We assessed exposure to GLP‐1 RAs in patients with type 2 diabetes and subsequent diagnosis of dementia in two large data sources with long‐term follow‐up: pooled data from three randomized double‐blind placebo‐controlled cardiovascular outcome trials (15,820 patients) and a nationwide Danish registry‐based cohort (120,054 patients). Results Dementia rate was lower both in patients randomized to GLP‐1 RAs versus placebo (hazard ratio [HR]: 0.47 (95% confidence interval [CI]: 0.25–0.86) and in the nationwide cohort (HR: 0.89; 95% CI: 0.86–0.93 with yearly increased exposure to GLP‐1 RAs). Discussion Treatment with GLP‐1 RAs may provide a new opportunity to reduce the incidence of dementia in patients with type 2 diabetes.https://doi.org/10.1002/trc2.12268dementiaglucagon‐like peptide‐1 receptor agonistsrandomized controlled trialreal‐world evidencetype 2 diabetes |
| spellingShingle | Caroline Holm Nørgaard Sarah Friedrich Charlotte Thim Hansen Thomas Gerds Clive Ballard Daniel Vega Møller Lotte Bjerre Knudsen Kajsa Kvist Bernard Zinman Ellen Holm Christian Torp‐Pedersen Lina Steinrud Mørch Treatment with glucagon‐like peptide‐1 receptor agonists and incidence of dementia: Data from pooled double‐blind randomized controlled trials and nationwide disease and prescription registers Alzheimer’s & Dementia: Translational Research & Clinical Interventions dementia glucagon‐like peptide‐1 receptor agonists randomized controlled trial real‐world evidence type 2 diabetes |
| title | Treatment with glucagon‐like peptide‐1 receptor agonists and incidence of dementia: Data from pooled double‐blind randomized controlled trials and nationwide disease and prescription registers |
| title_full | Treatment with glucagon‐like peptide‐1 receptor agonists and incidence of dementia: Data from pooled double‐blind randomized controlled trials and nationwide disease and prescription registers |
| title_fullStr | Treatment with glucagon‐like peptide‐1 receptor agonists and incidence of dementia: Data from pooled double‐blind randomized controlled trials and nationwide disease and prescription registers |
| title_full_unstemmed | Treatment with glucagon‐like peptide‐1 receptor agonists and incidence of dementia: Data from pooled double‐blind randomized controlled trials and nationwide disease and prescription registers |
| title_short | Treatment with glucagon‐like peptide‐1 receptor agonists and incidence of dementia: Data from pooled double‐blind randomized controlled trials and nationwide disease and prescription registers |
| title_sort | treatment with glucagon like peptide 1 receptor agonists and incidence of dementia data from pooled double blind randomized controlled trials and nationwide disease and prescription registers |
| topic | dementia glucagon‐like peptide‐1 receptor agonists randomized controlled trial real‐world evidence type 2 diabetes |
| url | https://doi.org/10.1002/trc2.12268 |
| work_keys_str_mv | AT carolineholmnørgaard treatmentwithglucagonlikepeptide1receptoragonistsandincidenceofdementiadatafrompooleddoubleblindrandomizedcontrolledtrialsandnationwidediseaseandprescriptionregisters AT sarahfriedrich treatmentwithglucagonlikepeptide1receptoragonistsandincidenceofdementiadatafrompooleddoubleblindrandomizedcontrolledtrialsandnationwidediseaseandprescriptionregisters AT charlottethimhansen treatmentwithglucagonlikepeptide1receptoragonistsandincidenceofdementiadatafrompooleddoubleblindrandomizedcontrolledtrialsandnationwidediseaseandprescriptionregisters AT thomasgerds treatmentwithglucagonlikepeptide1receptoragonistsandincidenceofdementiadatafrompooleddoubleblindrandomizedcontrolledtrialsandnationwidediseaseandprescriptionregisters AT cliveballard treatmentwithglucagonlikepeptide1receptoragonistsandincidenceofdementiadatafrompooleddoubleblindrandomizedcontrolledtrialsandnationwidediseaseandprescriptionregisters AT danielvegamøller treatmentwithglucagonlikepeptide1receptoragonistsandincidenceofdementiadatafrompooleddoubleblindrandomizedcontrolledtrialsandnationwidediseaseandprescriptionregisters AT lottebjerreknudsen treatmentwithglucagonlikepeptide1receptoragonistsandincidenceofdementiadatafrompooleddoubleblindrandomizedcontrolledtrialsandnationwidediseaseandprescriptionregisters AT kajsakvist treatmentwithglucagonlikepeptide1receptoragonistsandincidenceofdementiadatafrompooleddoubleblindrandomizedcontrolledtrialsandnationwidediseaseandprescriptionregisters AT bernardzinman treatmentwithglucagonlikepeptide1receptoragonistsandincidenceofdementiadatafrompooleddoubleblindrandomizedcontrolledtrialsandnationwidediseaseandprescriptionregisters AT ellenholm treatmentwithglucagonlikepeptide1receptoragonistsandincidenceofdementiadatafrompooleddoubleblindrandomizedcontrolledtrialsandnationwidediseaseandprescriptionregisters AT christiantorppedersen treatmentwithglucagonlikepeptide1receptoragonistsandincidenceofdementiadatafrompooleddoubleblindrandomizedcontrolledtrialsandnationwidediseaseandprescriptionregisters AT linasteinrudmørch treatmentwithglucagonlikepeptide1receptoragonistsandincidenceofdementiadatafrompooleddoubleblindrandomizedcontrolledtrialsandnationwidediseaseandprescriptionregisters |